Elicera Therapeutics AB Total Liabilities

Latest as of September 2025: Skr6.97 Million SEK ≈ $750.01K USD

Elicera Therapeutics AB total liabilities. Based on the latest financial reports, Elicera Therapeutics AB (ELIC) has total liabilities worth Skr6.97 Million SEK (≈ $750.01K USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check ELIC asset resilience ratio to evaluate the company's liquid asset resilience ratio.

Total Liabilities of Elicera Therapeutics AB (2014–2024)

Total liabilities of Elicera Therapeutics AB from 2014 to 2024. This chart illustrates how Elicera Therapeutics AB's total liabilities have evolved over time, based on quarterly financial data.

Elicera Therapeutics AB Competitors by Total Liabilities

The table below lists competitors of Elicera Therapeutics AB ranked by their total liabilities.

Company	Country	Total Liabilities
Samil Co.Ltd KQ:032280	Korea	₩41.68 Billion
HK Co. Ltd KQ:044780	Korea	₩23.08 Billion
Thanasiri Group Public Company Limited BK:THANA	Thailand	฿579.66 Million
Dantax CO:DANT	Denmark	Dkr5.84 Million
Vision Sigma TA:VISN	Israel	ILA284.59 Million
City Steel Public Company Limited BK:CITY	Thailand	฿19.28 Million
S. Pack & Print Public Company Limited BK:SPACK	Thailand	฿559.96 Million
Swoop Holdings Ltd AU:SWP	Australia	AU$56.86 Million

Liability Composition Analysis (2014–2024)

This chart breaks down Elicera Therapeutics AB's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see ELIC total asset value.

Liquidity & Leverage Metrics

Elicera Therapeutics AB Total Liabilities Ratios Explained

Elicera Therapeutics AB total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.

Metric	Value	Description
Current Ratio	5.35	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.23	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.19	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Elicera Therapeutics AB's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Elicera Therapeutics AB (2014–2024)

The table below shows the annual total liabilities of Elicera Therapeutics AB from 2014 to 2024.

Year	Total Liabilities	Change
2024-12-31	Skr6.79 Million ≈ $730.97K	-50.70%
2023-12-31	Skr13.78 Million ≈ $1.48 Million	+2.00%
2022-12-31	Skr13.51 Million ≈ $1.45 Million	+440.31%
2021-12-31	Skr2.50 Million ≈ $269.05K	+6.22%
2020-12-31	Skr2.35 Million ≈ $253.30K	+58742.88%
2019-12-31	Skr4.00K ≈ $430.46	0.00%
2018-12-31	Skr4.00K ≈ $430.46	0.00%
2017-12-31	Skr4.00K ≈ $430.46	-96.79%
2016-12-31	Skr124.60K ≈ $13.41K	-66.03%
2015-12-31	Skr366.76K ≈ $39.47K	-38.55%
2014-12-31	Skr596.87K ≈ $64.23K	--

About Elicera Therapeutics AB

ST:ELIC Sweden Biotechnology

Market Cap

$13.66 Million

Skr126.92 Million SEK

Market Cap Rank

#26103 Global

#532 in Sweden

Share Price

Skr2.62

Change (1 day)

-2.06%

52-Week Range

Skr2.30 - Skr6.80

All Time High

Skr8.56